Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.” ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

Cancer Monoclonal Antibody Market Cancer rates continue to rise, especially in aging populations and areas affected by pollution and lifest ...

However, Regeneron actually meets the definition of a biotech instead. The company became practically a household name when its monoclonal antibody COVID-19 therapy REGEN-COV2 was used to treat ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...